SecBot SecBot
PRESS-RELEASE ·Filed Jul 28, 2026

CHE

Chemed Corp.
BULLISH
Impact 7/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised guidance and VITAS's accelerating growth trajectory (ADC +6.1%, revenue +11.9%) with minimal Medicare Cap headwinds are the key catalysts. Traders should watch for continued share repurchases (10.5% share reduction over trailing 12 months) and monitor the July 29 conference call for further operational detail. The 17.8% YoY adjusted EPS growth implied by guidance midpoint supports further upside.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$539.36
T+0 close · Jul 28, 2026 · via day close
Latest settled
−3.56%
T+60 · $520.15
Vs SPY
−8.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $539.36entry
  2. T+1 · 4mo ago −0.85%α −2.52% · $534.79
  3. T+5 · 3mo ago +1.33%α −4.20% · $546.51
  4. T+20 · 3mo ago +1.71%α −3.31% · $548.56
  5. T+60 · 26d ago −3.56%α −8.29% · $520.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemed reported Q2 2026 GAAP EPS of $5.13 (up 43.7% YoY) and revenue of $673.3M (up 8.8% YoY), beating consensus estimates of $5.60 EPS and $665.0M revenue by 0.9% and 1.2%, respectively. The beat was driven by VITAS's strong performance, with revenue up 11.9% and a sharp reduction in Medicare Cap billing limitations ($0.5M vs $16.4M last year). Guidance was raised meaningfully, with full-year adjusted EPS now $25.00-$25.75 (up from $24.00-$24.75), and VITAS ADC/revenue growth and EBITDA margin targets all revised upward, making this a clear bullish catalyst.

Key Financial Metrics

EPS
$5.13
est $5.60 · -8.4%
Revenue
$673.3M
est $665.0M · +1.3% · +8.8% YoY
Rating
beat

Key Facts

  • Revenue $673.3M (+8.8% YoY) vs consensus $665.0M
  • GAAP diluted EPS $5.13 (+43.7% YoY) vs consensus $5.60
  • Adjusted diluted EPS $6.06 (+41.9% YoY)
  • VITAS net revenue $443.3M (+11.9% YoY), ADC up 6.1% to 23,687
  • Medicare Cap billing limitation dropped to $0.5M from $16.4M in Q2 2025
  • Roto-Rooter revenue $229.9M (+3.3% YoY), EBITDA essentially flat
  • Full-year adjusted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75
  • VITAS guidance raised: ADC growth 5.75%-6.25%, revenue growth ex-Medicare Cap 8.25%-9.25%, EBITDA margin 19.0%-19.5%
  • Company repurchased 210,000 shares for $89.8M in Q2, $139.8M remaining authorization
  • Cash $40.2M, long-term debt $140.0M, new $450M credit facility

Financial Impact

Revenue beat consensus by $8.3M (+1.2%); GAAP EPS beat consensus by $0.53 (+9.5%); adjusted EPS guidance midpoint raised by $1.00 (+4.1%)

revenueepsguidanceshare repurchasesMedicare Cap exposure

Risk Factors

  • Medicare Cap billing limitation of $7.0M still expected for full year 2026 across four provider numbers
  • Roto-Rooter EBITDA margin declining 77 bps to 21.1% and revenue growth slowing to 3.3%
  • High-acuity days-of-care declining 24 bps to 2.2% of total days, pressuring revenue per patient day
  • Significant share repurchase activity ($287.5M YTD) reduces float but also depletes cash reserves

Market Snapshot

Exchange
NYSE
Sector
Services-Home Health Care Services
Analyst Consensus
50% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3334743

Track record

19 reports on CHE

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $528.05 to $548.20 Now $549.45 +4.05% ▲ +3.82% +1.22% vs SPY
  2. Nov 5, 202611d ago Insider Cluster Bearish 4/10 Entry $533.77 to $550.20 Now $549.45 −2.94% ▼ −3.08% +0.21% vs SPY
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $533.65 to $544.49 Now $549.45 +2.96% ▲ +2.03% +2.62% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
  5. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  6. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
  7. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $512.98 to $534.72 Now $549.45 +7.11% ▲ +4.24% +4.80% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 1/10 Entry $502.90 to $498.25 Now $549.45 +9.26% ▼ −0.92% −2.23% vs SPY
  9. Sep 16, 20268w ago Press Release Neutral 4/10 Entry $505.97 to $495.65 Now $549.45 +8.59% ▼ −2.04% −2.64% vs SPY
  10. Aug 24, 202612w ago Insider Cluster Neutral 3/10 Entry $541.34 to $518.71 Now $549.45 +1.50% ▼ −4.18% −4.65% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 28, 2026